Clinical Trial Detail

NCT ID NCT04495257
Title A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Yale University
Indications

melanoma

renal cell carcinoma

Therapies

APX005M + Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.